Blood
Josep-Maria Ribera, Anna Torrent, Mireia Morgades, Susana Barrena, Jordi Ribera, Eulàlia Genescà, José González-Campos, Núria Martínez-Cibrian, Pau Montesinos, Alberto Hernández-Sánchez, Pere Barba, Edgar Zapico, Ricardo Sánchez, Andrés Novo, Marta Sitges, Clara Maluquer, Esperanza Such, Carmen Botella, Mari-Paz Queipo de Llano, Mónica Cabrero, Ana Vicent, Paula López de Ugarriza, Mar Tormo, Bernardo-Javier González-González, Irene García-Cadenas, Carlos Rodríguez-Medina, Pilar Martínez-Sánchez, Arancha Bermúdez, Ignacio Gómez-Centurión, María Herrero, Juana Ciudad, Josgrey Navas-Acosta, Lourdes Hermosín, Josefina Serrano, José-Ángel Raposo, Laura Solán, Verónica Roldán-Galiacho, Almudena de Laiglesia, Lucía Gómez-Pérez, María Solé-Rodríguez
Abstract In adults with Philadelphia chromosome–negative (Ph−) acute lymphoblastic leukemia (ALL) genetic risk is usually combined with measurable residual disease (MRD) assignment to consolidation therapy. However, this combination is not uniform across trials and centralized assessment is not always performed. This study analyzed patient outcomes using centrally assessed MRD and genetics. Patients with high genetic risk (HGR), those who required 2 induction cycles for complete remission (CR), and patients with CR …
2 Zitationen